To identify new biological pathways in ccRCC that could be therapeutically targetable, we conducted RNA-Seq of 5 independent ccRCC cell lines derived from the Vhl/Trp53/Rb1-deficient autochthonous mouse ccRCC model (34) and compared the RNA-Seq data with RNA-Seq data from 3 cultures of normal primary mouse renal epithelial cells from the same genetic background (Supplemental Data 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.156087DS1). The gene discussed is TP53; the disease is nonpapillary renal cell carcinoma.